Watson/Aventis diltiazem agreement
Executive Summary
Watson will report a gain of $60 mil. resulting from its settlement with Aventis over the diltiazem product Dilacor XR. Watson licensed Dilacor from Rhone-Poulenc Rorer, which required RPR not to sell a competing product; RPR gained Hoechst's Cardizem (diltiazem) line in the Aventis merger. Biovail acquired North American rights to the branded diltiazem product line from Aventis in January (1"The Pink Sheet" Jan 8, p. 21)